I-Mab

181 articles about I-Mab

• I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

  4/5/2024

  I-Mab announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

• I-Mab Announces Participation at Jefferies and Piper Conferences in November

  11/6/2023

  I-Mab today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.

• Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

  11/2/2023

  I-Mab and HI-Bio announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy.

• I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

  11/1/2023

  I-Mab today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer's (SITC) Annual Meeting, taking place November 1-5, 2023

• I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

  10/10/2023

  I-Mab today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380).

• 

  AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

  9/25/2023

  After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.

• I-Mab Announces Upcoming Participation at September Conferences - September 5, 2023

  9/5/2023

  I-Mab today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows.

• I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

  8/17/2023

  I-Mab announced its financial results for the six months ended June 30, 2023, and provided key business updates.

• I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

  8/8/2023

  I-Mab today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023.

• TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma

  7/11/2023

  TRACON Pharmaceuticals announced it has collected the previously announced arbitration award from I-Mab Biopharma.

• I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

  7/5/2023

  I-Mab today announced the publication of a manuscript entitled "CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation" in the latest issue of The Journal for Immuno-Therapy of Cancer (JITC).

• I-Mab Announces the Appointment of Raj Kannan as CEO

  6/22/2023

  I-Mab today announced the appointment of Mr. Raj Kannan as the Company's new Chief Executive Officer and a member of the board of directors.

• TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

  6/15/2023

  TRACON Pharmaceuticals, Inc. announced that it has commenced court proceedings in Hong Kong and the Cayman Islands to enforce an April 2023 arbitration award against I-Mab for approximately $23.0 million, plus interest.

• I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

  5/25/2023

  I-Mab announced encouraging results from the Phase 1b/2 study evaluating uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination with toripalimab, a PD-1 antibody, in patients with treatment-naïve advanced non-small cell lung cancer, and exploring the potential value of CD73 expression as a predictive biomarker.

• I-MAB Filed 2022 Annual Report on Form 20-F

  5/1/2023

  I-Mab announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission on May 1, 2023.

• I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

  4/26/2023

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination with PD-1 therapy in non-small-cell lung cancer (NSCLC), will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

  4/25/2023

  TRACON Pharmaceuticals, Inc. today announced that the tribunal in the arbitration against I-Mab conducted under the Rules of Arbitration of the International Chamber of Commerce (ICC) rendered an award to TRACON in the aggregate amount of approximately $23.0 million.

• I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

  3/31/2023

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.

• I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

  3/20/2023

  I-Mab today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

• I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

  10/5/2022

   I-Mab today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.